Janusq LLC
Rocky River, OH
- UEI
- DKRHA61KMNX4
- CAGE
- 8DP47
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 1953 Wynwood Dr, Rocky River, OH 44116, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of alzheimer's disease - project… | National Institute on Aging | $1,153,328 | |
| In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the treatment of huntington's… | National Institute of Neurological Disorders and Stroke | $698,011 | |
| Pharmacokinetic and pharmacodynamic assessment of peptide-based therapy DA1 for the treatment of alzheimer's disease -… | National Institute on Aging | $519,168 | |
| Pharmacokinetic assessment of peptide-based therapy HV-3 for the treatment of huntington's disease - project… | National Institute of Neurological Disorders and Stroke | $722,814 |
About Janusq LLC
Janusq LLC is a startup biotechnology company spun out of Case Western Reserve University, focused on developing innovative peptide-based therapies targeting neurodegenerative diseases. Specializing in advanced medical research, the company concentrates on addressing mitochondrial dysfunction associated with conditions like Alzheimer's disease and Huntington's disease through sophisticated peptide interventions.
The company has secured multiple federal grants from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, totaling over $1 million in funding for targeted research projects. These grants support the development of specific peptide therapies, including DA1, DA45, and HV-3, which aim to disrupt protein interactions and mitigate mitochondrial dysfunction in neurodegenerative conditions. Each research project involves comprehensive pharmacokinetic assessments, in vivo efficacy studies, and safety evaluations using mouse models. The grants, structured as Small Business Innovation Research (SBIR) awards, enable Janusq to investigate peptide stability, brain tissue penetration, and potential therapeutic impacts on neurological disorders. The research focuses on understanding molecular mechanisms of diseases like Alzheimer's and Huntington's, with the ultimate goal of developing potential treatment strategies that address underlying cellular dysfunction rather than just managing symptoms.
Quick answers
What is Janusq LLC's UEI?
Janusq LLC's Unique Entity ID (UEI) in SAM.gov is DKRHA61KMNX4.
What is Janusq LLC's CAGE code?
Janusq LLC's CAGE code is 8DP47.
Where is Janusq LLC located?
Janusq LLC's physical address in SAM.gov is 1953 Wynwood Dr, Rocky River, OH 44116, USA.
Is Janusq LLC registered in SAM.gov?
Yes. Janusq LLC's SAM.gov registration is active through January 7, 2027.
What is Janusq LLC's most recent federal award?
Janusq LLC's most recent federal grant award is Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of alzheimer's disease - project… (R43AG097351), from National Institute on Aging, on September 22, 2025.
On GovTribe
See Janusq LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors